SCHEMBL6011852

SCHEMBL6011852

CCC(N)(C(=O)O)c1ccc(C(=N)N)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.73
CYP1A2 P05177 1/20 0.73
KMT2A Q03164 1/20 0.73
NQO2 P16083 6/20 0.44
PRSS1 P07477 4/20 0.44
PRSS2 P07478 4/20 0.44
PRSS3 P35030 4/20 0.44
F2 P00734 3/20 0.44
PLG P00747 1/20 0.44
C1S P09871 1/20 0.44
CPN1 P15169 1/20 0.41
CPB2 Q96IY4 1/20 0.41
TMPRSS6 Q8IU80 1/20 0.40
ST14 Q9Y5Y6 1/20 0.40
F10 P00742 2/20 0.39
F12 P00748 1/20 0.39
F7 P08709 1/20 0.39
F3 P13726 1/20 0.39
PKM P14618 1/20 0.39
LOXL2 Q9Y4K0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13073529 0.84 MEN1 (1.00) MEN1CYP1A2KMT2AGRM5GRM1
SCHEMBL8905131 0.81 MEN1 (0.47) MEN1CYP1A2KMT2ANQO2PRSS1
Hydrochloric Acid SCHEMBL8500969 0.80 KMT2A (0.46) MEN1CYP1A2KMT2ANQO2PRSS1
SCHEMBL27338628 0.79 MEN1 (0.71) MEN1CYP1A2KMT2A
SCHEMBL8503418 0.78 MEN1 (0.45) MEN1CYP1A2KMT2ANQO2PRSS1
SCHEMBL305912 0.78 CYP1A2 (0.70) MEN1CYP1A2KMT2AGRM5GRM1
SCHEMBL2089243 0.78 CYP1A2 (0.70) MEN1CYP1A2KMT2AGRM5GRM1
SCHEMBL2089245 0.78 CYP1A2 (0.70) MEN1CYP1A2KMT2AGRM5GRM1
SCHEMBL7742622 0.77 MEN1 (0.69) MEN1CYP1A2KMT2A
SCHEMBL21767930 0.77 MEN1 (0.69) MEN1CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025120038-A1 METHOD AND DEVICES FOR DETECTING A FIBRINOGEN LEVEL IN A SAMPLE ROCHE DIAGNOSTICS GMBH (DE) 2025-06-12 WO disclosed
US-20160257708-A1 ACYLATED 4-AMIDINO- AND 4-GUANIDINOBENZYLAMINES FOR THE INHIBITION OF PLASMA KALLIKREIN CURACYTE CHEMISTRY GMBH (DE) 2016-09-08 US disclosed
US-9365613-B2 Acylated 4-amidino- and -4-guanidinobenzylamines for inhibition of plasma kallikrein THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2016-06-14 US disclosed
US-20060148901-A1 Acylated 4-amidino-and-4-guanidinobenzylamines for inhibition of plasma kallikrein THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148901-A1 Acylated 4-amidino-and-4-guanidinobenzylamines for inhibition of plasma kallikrein F12, F11, F2 MEN1 1307/4885CYP1A2 1363/4885KMT2A 372/4885
US-20160257708-A1 ACYLATED 4-AMIDINO- AND 4-GUANIDINOBENZYLAMINES FOR THE INHIBITION OF PLASMA KALLIKREIN F12, F2, F11 MEN1 1321/4885CYP1A2 1369/4885KMT2A 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.